Technical Analysis for PRAX - Praxis Precision Medicines, Inc.

Grade Last Price % Change Price Change
C 4.34 -3.34% -0.15
PRAX closed down 3.34 percent on Wednesday, February 8, 2023, on 77 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: Feb 27
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Down

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible NR7 about 8 hours ago
Possible Inside Day about 8 hours ago
60 Minute Opening Range Breakout about 11 hours ago
20 DMA Support about 12 hours ago
Down 3% about 13 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Praxis Precision Medicines, Inc. Description

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement Purdue Neuroscience Company; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Neuroscience Precision Medicine Epilepsy Central Nervous System Disorders Nervous System Disorders Major Depressive Disorder Depression Depressive Disorder Huntington's Disease Oligonucleotide Treatment Of Major Depressive Disorder Spinal Muscular Atrophy Neuron Antisense RNA Essential Tremor Receptor Positive Ionis Perimenopausal Depression

Is PRAX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 14.25
52 Week Low 1.48
Average Volume 1,113,978
200-Day Moving Average 3.71
50-Day Moving Average 3.09
20-Day Moving Average 4.29
10-Day Moving Average 4.67
Average True Range 0.40
RSI 58.51
ADX 56.0
+DI 27.29
-DI 12.76
Chandelier Exit (Long, 3 ATRs) 4.05
Chandelier Exit (Short, 3 ATRs) 3.57
Upper Bollinger Bands 5.44
Lower Bollinger Band 3.14
Percent B (%b) 0.52
BandWidth 53.61
MACD Line 0.46
MACD Signal Line 0.54
MACD Histogram -0.0771
Fundamentals Value
Market Cap 166.06 Million
Num Shares 38.3 Million
Price-to-Sales 0.00
Price-to-Book 95.89
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.60
Resistance 3 (R3) 4.61 4.54 4.56
Resistance 2 (R2) 4.54 4.47 4.53 4.54
Resistance 1 (R1) 4.44 4.43 4.40 4.43 4.53
Pivot Point 4.36 4.36 4.34 4.36 4.36
Support 1 (S1) 4.26 4.29 4.23 4.25 4.15
Support 2 (S2) 4.19 4.25 4.18 4.14
Support 3 (S3) 4.09 4.19 4.12
Support 4 (S4) 4.08